CD2-mediated CD59 stimulation in keratinocytes results in secretion of IL-1α, IL-6, and GM-CSF: Implications for the interaction of keratinocytes with intraepidermal T lymphocytes

International Journal of Molecular Medicine

Volumn 3, Issue 6, 1999, Pages 609-614

  Naderi, S ^a,b   Hofmann, P ^b   Seiter, S ^c   Tilgen, W ^b,c   Abken, H ^b,c   Reinhold, U ^a,c  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

CD2 ligation; CD59; Cytokines; Keratinocytes

Indexed keywords

BLOCKING ANTIBODY; CD2 ANTIGEN; CD59 ANTIGEN; COMPLEMENT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 6; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; PHOSPHATIDYLINOSITOL DIACYLGLYCEROL LYASE; PHOSPHOLIPASE C;

ARTICLE; BIOSYNTHESIS; CELL COMMUNICATION; CELL LINE; CELL STRAIN HL 60; CELL STRAIN K 562; CYTOLOGY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HUMAN; IMMUNOLOGY; KERATINOCYTE; METABOLISM; PHYSIOLOGY; SECRETION; T LYMPHOCYTE;

ANTIBODIES, BLOCKING; ANTIGENS, CD2; ANTIGENS, CD58; ANTIGENS, CD59; CELL COMMUNICATION; CELL LINE; COMPLEMENT SYSTEM PROTEINS; GENE EXPRESSION REGULATION; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HL-60 CELLS; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; K562 CELLS; KERATINOCYTES; PHOSPHATIDYLINOSITOL DIACYLGLYCEROL-LYASE; PHOSPHOLIPASE C; T-LYMPHOCYTES; TRANSFECTION;

EID: 0033145223     PISSN: 11073756     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Davies A, Simmons DL, Hale G, Harrison RA, Tighe H, Lachmann PJ and Waldmann H: CD59, an LY 6-likc protein expressed in human lymphoid cells, regulates the action of complement membrane attack complex on homoloeous cells. J ExpMed 170: 637-654, 1989.
2. Okada N, Harada R, Fujita T and Okada H: A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complement. Int Immunol 1: 205-208, 1989.
3. Meri S, Morgan BP, Davies A, Daniels RH, Olavesen MG, Waldmann H and Lachmann PJ: Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid layers. Immunology 71: 1-9, 1990.
4. Rollins SA and Sims PJ: The complement inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J Immunol 144: 3478-3483, 1990.
5. Rollins SA, Zhaou J, Ninomiya H and Sims PJ: Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9. J Immunol 146: 2345-2351, 1991.
6. Meri S, Waldmann H and Lachmann PJ: Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab Invest 65: 532-537, 1991.
7. Niehans GA, Cherwitz DL, Staley NA, Knapp DJ and Dalmasso AP: Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am J Pathol 149: 129-142, 1996.
8. Holmes CH, Simpson KL, Okada H, Okada N, Wainwright SD, Purcell DFJ and Houlihan JM: Complement regulatory proteins at the fetomatemal interface during human placental development: distribution of CD59 by comparison with membrane cofactor protein (GD46) and decay accelerating factor (CD55). Eur J Immunol 22: 1579-1585, 1992.
9. Venneker GT, Das PK, Meinardi MMHM, van Marie J, van Veen HA, Bos JD and Asghar SS: Glycosylphosphatidylinositol (GPI)-anchored membrane proteins are constitutively down-regulated in psoriatic skin. J Pathol 172: 189-197, 1994.
10. Holguin MH, Fredrick LR, Bernshaw NJ, Wilcox LA and Parker CJ: Isolation and characterisation of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal haemoglobinuria. J Clin Invest 84: 7-17, 1989.
11. Brasoveanu LI, Altomontc M, Fonsatti E, Colizzi F, Coral S, Nicotra MR, Cattarossi I, Cattelan I, Natali PG and Maio M: Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells. Lab Invest 74: 33-42, 1996.
12. Gorter A, Blok VT, Haasnoot WHB, Ensink NG, Doha MR and Fleuren GJ: Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis. Lab Invest 74: 1039-1049, 1996.
13. Morgan BP, van den Berg CW, Davics EV, Hallett MB and Horejsi V: Cross-linking of CD59 and of other glycosyl phosphatidylinositol-anchorcd molecules on neutrophils trigger cell activation via tyrosine kinase. Eur J Immunol 23: 2841-2850, 1993.
14. Korty PE, Brando C and Shevach EM: CD59 functions as a signal-transducing molecule for human T cell activation. J Immunol 146: 4092-4098, 1991.
15. Deckert M, Kubar J, Zoccola D, Bernard-Pomier G, Angelisova P, Horejsi V and Bernard A: CD59 molecule: a second ligand for CD2 in T cell adhesion. Eur J Immunol 22: 2943-2947, 1992.
16. Hahn WC, Menu E, Bothwcll ALM, Sims PJ and Bierer BE: Overlapping but not identical binding sites on CD2 for CD58 and a second ligand CD59. Science 256: 1805-1807, 1992.
17. Sayama K, Shiraishi S, Shirakata Y, Kobayashi Y, Okada H and Miki Y: Characterization of homologous restriction factor (HRF20) in human skin and leucocytes. Clin Exp Immunol 82: 355-358, 1990.
18. Rheinwald JG and Green H: Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. Cell 6: 331-343, 1975.
19. Boukamp P, Petrussevska RT, Breitkreuz D, Hornung J, Markham A and Fusenig NE: Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 106: 761-771, 1988.
20. Fletcher A, Bryant JA, Gardner B, Judson PA, Spring FA, Parsons SF, Mallinson G and Anstce DJ: New monoclonal antibodies in CD59: use for the analysis of peripheral-blood cells i from paroxysmal nocturnal hacmoglobinurie (PNH) patients and for the quantification of CD59 on normal and decay accelerating factor (DAF)-deficient erythrocytes. Immunology 75: 507-512, 1992.
21. Sedlak J, Hunakova L, Duraj J, Grofova M and Chorvath B: Modulation of protectin (CD59 antigen) cell surface expression on human neoplastic cell lines. Neoplasma 40: 337-340, 1993.
22. Bjorge L and Matre R: Down-regulation of CD59 (protectin) expression on human colorectal adenocarcinoma cell lines by levamisole. Scand J Immunol 42: 512-516, 1995.
23. Marchbank KJ, Morgan BP and van den Berg CW: Regulation of CD59 expression on K562 cells: effects of phorbol myristate acetate, cross-linking antibody and non-lethal complement attack. Immunology 85: 146-152, 1995.
24. Holguin MH, Martin CB, Eggett T and Parker CJ: Analysis of the gene that encodes the complement regulatory protein, membrane inhibitor of reactive lysis (CD59). J Immunol 157: 1659-1668, 1996.
25. Lund-Johansen F, Olwus J, Symington FW, Arli A, Thompson JS, Vilella R, Skubitz K and Horejsi V: Activation of human monocytes and granulocytes by monoclonal antibodies to glycosylphosphatidylinositol-anchored antigens. Eur J Immunol 23: 2782-2791, 1993.
26. 2+-signalling competent. J Cell Biol 131: 669-677, 1995.
27. Van der Merwe PA, Barclay AN, Mason DW, Davies EA, Morgan BP, Tone M, Krishnam AKC, Ianelli C and Davis SJ: Human cell-adhesion molecule CD2 binds CD58 (LFA-3) with a very low affinity and an extremely fast dissociation rate but does not bind CD48 or CD59. Biochemistry 33: 10149-10160, 1994.
28. Shimizu Y, Mobley JL, Finkelstein LD and Chan ASH: A role for phosphatidylinositol 3-kinasc in the regulation of ß1 integrin activity by the CD2 antigen. J Cell Biol 131: 1867-1880, 1995.
29. Stoof TJ, Mitra RS, Sarma V, Dixit VM and Nickoloff BJ: Keratinocyte activation following T-lymphocyte binding. J Invest Dermatol 98: 92-95, 1992.